QUEBEC CITY, Jan. 22 /CNW Telbec/ - Victhom Human Bionics Inc. (Victhom,
TSX: VHB) announced today that it has received unconditional approval from the
Max Healthcare Institute Ethics Committee in New Delhi to begin the clinical
investigation of the Neurostep(TM) in India.
Mr. Nader Kameli, COO of Victhom's Neurobionix business unit, stated that
"Victhom could now start recruitment of patients in India to join the
currently ongoing international multi-center study on the Neurostep(TM)". He
added that "with the previously announced sites in Vancouver, Quebec City and
in the U.K., Victhom was now working with four sites in three countries around
the world". He also said: "I am glad we have received all necessary approvals
from all countries and centers that Victhom set out to work with".
Mr. Benoit Huet, President and CEO, stated the importance of this
clinical trial for the Neurostep(TM) and added that the company was on target
to deliver preliminary efficacy and safety results on the Neurostep(TM) during
the first half of 2008, which represents a major milestone in the development
of this technology.
The Neurostep(TM) is the first fully implantable product designed to
treat, through neuromodulation, gait disorders (e.g., foot drop) which can
result from a lesion of the central nervous system caused by conditions such
as stroke and multiple sclerosis. There are more than 1,400,000 new cases of
stroke per year worldwide and approximately 20 to 30% of these patients will
develop symptoms of foot drop. The Closed-Loop System of the Neurostep(TM)
allows the combination of the sensing and stimulating features to widen the
scope of therapeutic possibilities as compared to conventional technologies
that use stimulation only.
Victhom discovers, develops and manufactures bionic devices involved in
the treatment of a variety of physical and physiological dysfunctions.
Victhom's Neurobionix business unit focuses on the development and
commercialization of technologies and products involving implantable devices
that feature neurosensing and neurostimulation components, integrated with
artificial intelligence. Victhom's Biotronix business unit develops
biomechatronic products to support or replace peripheral limbs in what is
known as the orthotics and prosthetics market.
Some of the statements made herein may constitute forward-looking
statements. These statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and other
factors that may cause Victhom's actual results, performance or achievements
to be materially different from those expressed or implied by any of Victhom's
statements. Actual events or results may differ materially. We disclaim any
intention, and assume no obligation, to update these forward-looking
For further information:
For further information: Mr. Benoit Huet, President & CEO, Victhom Human
Bionics, (418) 872-5665, Fax: (418) 872-6926, email@example.com,
www.victhom.com; Source: Victhom Human Bionics Inc.